Dopamine vs noradrenaline: inverted-U effects and ADHD theories

References

• Biederman J, Baldessarini RJ, Wright W, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD. J Am Acad Child Adolesc Psychiatry 1985; 28: 777–784
   Web of Science ®Google Scholar
• Zametkin AJ, Rappaport JL, Murphy DL, Linnoila M, Ishmond D. Treatment of hyperactive children with monoamine oxidase inhibitors. 1. Clinical efficacy. Arch Gen Psychiatry 1885; 42: 962–966
   Google Scholar
• Levy F. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 1991; 25: 277–283
   PubMed Web of Science ®Google Scholar
• Coyle J, Snyder S. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther 1969; 170: 221–231
   PubMed Web of Science ®Google Scholar
• Taylor M, Snyder SH. Amphetamine: differentiation by d- and l- isomers of behaviour involving brain norepinephrine or dopamine. Science 1970; 168: 1487–1488
   PubMed Web of Science ®Google Scholar
• Harris JE, Balsessarini R. Uptake of [3H]-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropsychopharmacology 1973; 12: 669–679
   Google Scholar
• Levy F, Hobbes G. The action of stimulant medication in attention deficit disorder with hyperactivity: dopaminergic, noradrenergic, or both?. J Am Acad Child Adolesc Psychiatry 1988; 27: 802–805
   PubMed Web of Science ®Google Scholar
• Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1977; 198: 1274–1276
   PubMed Web of Science ®Google Scholar
• Grossberg S. Neural models of normal and abnormal behavior: what do schizophrenia, parkinsonism, and attention deficit disorder, and depression have in common?. Prog Brain Res 1999; 121: 375–406
   PubMedGoogle Scholar
• Evans SW, Pelham WE. Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol 1991; 19: 537–552
   PubMed Web of Science ®Google Scholar
• Douglas VI, Barr RG, Desilets J, Sherman E. Do high doses of stimulants impair flexible thinking in Attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry 1994; 34: 877–885
   Web of Science ®Google Scholar
• Solanto MV, Wender EH. Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity. Psychol Bull 1989; 26: 897–902
   Google Scholar
• Tannock R, Schachar R. Methylphenidate and cognitive perserveration in hyperactive children. J Child Psychol Psychiatry 1992; 33: 1217–1228
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007; 17: i6–i15
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. Cellular basis of working memory. Neuron 1995; 14: 477–485
   PubMed Web of Science ®Google Scholar
• Brozoski T, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205: 929–931
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31: 2376–2383
   PubMed Web of Science ®Google Scholar
• Williams GV, Goldman-Rakic PS. Blockade of dopamine D1 receptors enhances memory fields of prefrontal neurons in primate cerebral cortex. Nature 1995; 376: 572–575
   PubMed Web of Science ®Google Scholar
• Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007; 10: 376–384
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. Circuitry of primate prefrontal cortex and regulation of behaviour by representation memory In: Mountcastle VB, Plum F, Geiger SR. Handbook of physiology: the nervous system. Higher functions of the brain Bethesda, MD: American Physiological Society, 1987:373–417.
   Google Scholar
• Arnsten AFT, Goldman-Rakic PS. Alpha-2 adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 1985; 230: 1273–1276
   PubMed Web of Science ®Google Scholar
• Arnsten AFT, Robbins TW. Neurochemical modulation of prefrontal cortical function in humans and animals. Principles of frontal lobe function, DT Stuss, RT Knight. Oxford University Press, New York 2002; 51–84
   Google Scholar
• Arnsten AFT, Li B-M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005; 57: 1377–1384
   PubMed Web of Science ®Google Scholar
• Schultz W. The phasic reward signal of primate dopamine neurons. Adv Pharmacol 1998; 42: 686–690
   PubMedGoogle Scholar
• Ramos B, Stark D, Verduzco L, van Dyck CH, Arnsten AFT. Alpha-2A-adrenoreceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signalling in aging animals. Learn Mem 2006; 13: 770–776
   PubMed Web of Science ®Google Scholar
• Casey BJ, Castellanos FX, Giedd JN, et al. Implication of right frontostriatal circuitry in response inhibition and attention deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1997; 36: 374–383
   PubMed Web of Science ®Google Scholar
• Giedd JN, Castellanos FX, Casey BJ, et al. Quantitative morphology of the corpus callosum in attention deficit hyperactivity disorder. Am J Psychiatry 1994; 51: 665–669
   Google Scholar
• Castellanos FX, Giedd JN, Marsh WL, et al. Quantitative brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 607–616
   PubMed Web of Science ®Google Scholar
• Lewis DA, Gonzalez-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacol Rev 2008; 33: 141–165
   PubMed Web of Science ®Google Scholar
• Lewis DA, Gonzalez-Burgos G. Physiologically based treatment interventions in schizophrenia. Nat Med 2006; 12: 1016–1022
   PubMed Web of Science ®Google Scholar
• Gonzalez-Burgos G, Kroner S, Krimer LS, et al. Dopamine modulation of neuronal function in the monkey prefrontal cortex. Physiol Behav 2002; 77: 537–543
   PubMed Web of Science ®Google Scholar
• Sawaguchi T. The effects of dopamine and its antagonists on directional delay-period activity of prefrontal neurons in monkeys during an oculomotor delayed-response task. Neurosci Res 2001; 41: 115–128
   PubMed Web of Science ®Google Scholar
• Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine Dl receptors in prefrontal cortex. Nature 1995; 376: 572–575
   PubMed Web of Science ®Google Scholar
• Rotaru DC, Lewis DA, Gonzalez-Burgos G. Dopamine D1 receptor activation regulates sodium channel-dependent EPSP amplification in rat prefrontal cortex pyramidal neurons. J Physiol 2007; 581: 981–1000
   PubMed Web of Science ®Google Scholar
• Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74: 1–58
   PubMed Web of Science ®Google Scholar
• Castellanos FX. Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clin Pediatr 1997; 36: 381–393
   PubMed Web of Science ®Google Scholar
• Swanson J, Castellanos FX. Biological bases of attention deficit hyperactivity disorder: Neuroanatomy, Genetics and Pathophysiology. NIH Consensus Conference on ADHD. NIH, Rockville, MD 1998
   Google Scholar
• Frank MJ, Santamaria A, O'Reilly RC, Willcutt E. Testing computational models of dopamine and noradrenaline dysfunction in attention/deficit hyperactivity disorder. Neuropsychopharmacology 2007; 32: 1583–1599
   PubMed Web of Science ®Google Scholar
• Sonuga-Barke EJS. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 2003; 27: 593–604
   PubMed Web of Science ®Google Scholar
• Castellanos FX, Sonuga-Barke EJS, Scheres A, Di Martino A, Hyde C, Walters JR. Varieties of attention-deficit/hyperactivity disorder-related intra-individual variability. Biol Psychiatry 2005; 57: 1416–1423
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998; 2: 436–447
   PubMed Web of Science ®Google Scholar
• Arnsten A, Steere JC, Hunt RD. The contribution of alpha sub2-noradrenergic mechanisms to prefrontal cortical cognitive function: potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996; 53: 448–455
   PubMed Web of Science ®Google Scholar
• Arnsten AFT, Steere JC, Jentsch DJ, Li BM. Noradrenergic influences on prefrontal cortical cognitive function: opposing actions at post-junctional alpha1 versus alpha2− adrenergic receptors. Adv Pharmacol 1998; 42: 764–767
   PubMedGoogle Scholar
• Arnsten AFT, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through a2 adrenoreceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005; 1: 2
   PubMed Web of Science ®Google Scholar
• Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60: 1111–1120
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Scahill L, Findling RL. alpha-2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007; 17: 393–406
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled, study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatr 2008; 121: e73–e84
   PubMed Web of Science ®Google Scholar
• Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42: 886–894
   PubMed Web of Science ®Google Scholar
• Martinussen R, Hayden J, Hogg-Johnson S, Tannock J. A meta-analysis of working memory impairments in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 377–384
   PubMed Web of Science ®Google Scholar
• Nigg JT. Neuropsychologic theory and findings in attention/deficit hyperactivity disorder: the state of the field and salient changes for the coming decade. Biol Psychiatry 2005; 57: 1424–1435
   PubMed Web of Science ®Google Scholar
• Kerns KA, McInerney RJ, Wilde J. Time reproduction, working memory, and behavioural inhibition in children with ADHD. Child Neuropsychol 2001; 7: 21–31
   PubMed Web of Science ®Google Scholar
• Barnett R, Maruff P, Vance A, et al. Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychol Med 2001; 31: 1107–1115
   PubMed Web of Science ®Google Scholar
• Cook EH, Stein MA, Krasowski MD, et al. Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993–998
   PubMed Web of Science ®Google Scholar
• Gill M, Daly G, Heron S, Hawl Z, Fitzgerald M. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 1997; 2: 311–313
   PubMed Web of Science ®Google Scholar
• LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry 1996; 1: 121–124
   PubMed Web of Science ®Google Scholar
• Swanson JM, Sunahara GA, Kennedy JL, et al. Association of the dopamine receptor D4 (DRD4) gene with a referred phenotype of attention deficit hyperactivity disorder (ADHD): a family-based approach. Mol Psychiatry 1998; 3: 38–41
   PubMed Web of Science ®Google Scholar
• Smalley SL, Bailey JN, Palmer CG, et al. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol Psychiatry 1998; 3: 427–430
   PubMed Web of Science ®Google Scholar
• Comings DE, Gade-Andavolu R, Gonzalez N, et al. Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clin Genet 2000; 58: 31–40
   PubMed Web of Science ®Google Scholar
• Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–1323
   PubMed Web of Science ®Google Scholar
• Swanson JM, Kinsbourne M, Nigg J, et al. Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 2007; 17: 39–59
   PubMed Web of Science ®Google Scholar
• Levy F. Pharmacological and therapeutic directions in ADHD: specificity in the PFC. Behav Brain Funct 2008; 4: 12
   PubMed Web of Science ®Google Scholar
• Cheon K-A, Jun J-Y, Cho D-Y. Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit-hyperactivity disorder. Int Clin Psychopharmacol 2008; 23: 291–298
   PubMed Web of Science ®Google Scholar